Mouse Study Data on Akkermansia Muciniphila and SARS-CoV-2 Immune Response

A 13.0 KB Excel file contains results from a study using K18-hACE2 transgenic mice to investigate the gut-lung axis during SARS-CoV-2 infection. The data, authored by Gi-Cheon Kim and last updated in March 2026, likely includes measurements of weight loss, lung pathology, immune cell phenotypes, and cytokine production. Prophylactic administration of the gut bacterium Akkermansia muciniphila was found to enhance local antiviral immunity and reduce disease severity.

Use Cases

• Analyze correlations between gut microbiome shifts and lung pathology based on post-infection microbial composition data.
• Model the protective effects of Akkermansia muciniphila based on weight loss and histopathology outcome measures.
• Investigate immune cell phenotype changes, such as tissue-resident memory T cell expansion, following bacterial intervention.
• Study cytokine production profiles (e.g., Th2, Th17) in relation to prophylactic treatment described in the methods.

Strengths

• Data is derived from a controlled transgenic mouse model (K18-hACE2) for SARS-CoV-2 infection.
• The dataset is licensed under CC-BY-4.0, allowing for open sharing and reuse.
• Specific outcome measures like weight loss, lung pathology, and cytokine production are detailed in the description.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 13.0 KB file size suggests a very limited scope, likely containing summary or processed results rather than raw experimental data.

Provenance

Source

figshare, authored by Gi-Cheon Kim.

Collection Method

Experimental data from a study administering live Akkermansia muciniphila to mice infected with SARS-CoV-2 variants (WA and Omicron).

Freshness

Last updated 2026-03-18 07:42:00; freshness should be verified.